Navigation path

Community Register of medicinal products

Community register of orphan medicinal products


GRANTED  

Product information

(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

EU orphan designation number: EU/3/05/328   
Active ingredient: (E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Indication: Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Sponsor: Celgene Europe Limited
1 Longwalk Road, Stockley Park, Uxbridge, Middlesex UB11 1DB, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/11/2005 Centralised Orphan - Designation EMEA/OD/056/05 (2005)4352 of 28/10/2005
23/10/2008 Centralised Orphan - Transfer of orphan designation EMEA/OD/056/05/T/01 (2008)6244 of 21/10/2008
30/09/2010 Centralised Orphan - Transfer of orphan designation EMEA/OD/056/05/T/02 (2010)6803 of 28/09/2010
30/05/2011 Other procedure -